Elanco Animal Health Incorporated ELAN
25.28 USD +0.70 (+2.87%)
Nov 4, 2026, 3:34 PM EST
24.62 Day range 25.46
19.40 52-week range 27.98
- YTD
- +11.69%
- 1 year
- +12.33%
Analyst view
Consensus: buy
Buy
Price target (mean) 30.23 +19.6% upside
Now 25.28
- Target (low)
- 24.00
- Target (mean)
- 30.23
- Target (high)
- 34.00
Ratings (0m) 16 13 buy · 3 hold · 0 sell
- Strong buy4
- Buy9
- Hold3
- Sell0
- Strong sell0
Recommendation trend
- This month 16
- 1 month ago 16
- 2 months ago 17
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | 0.20328 | 0.19 – 0.21 | 0.19 | +7.0% | 1.21B | +6.1% | 12 |
| Next quarter | 0.18323 | 0.17 – 0.195 | 0.13 | +40.9% | 1.19B | +4.2% | 11 |
| Current year | 1.13 | 1.10 – 1.15 | 0.94 | +20.3% | 5.13B | +8.8% | 14 |
| Next year | 1.27 | 1.22 – 1.40 | 1.13 | +12.6% | 5.41B | +5.4% | 14 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 29, 2026 | Morgan Stanley | Maintained | Equal-Weight | Equal-Weight |
| Oct 20, 2026 | Jefferies | Downgrade | Buy | Hold |
| Oct 16, 2026 | Goldman Sachs | Initiated | — | Buy |
| Aug 6, 2026 | UBS | Maintained | Buy | Buy |
| Aug 6, 2026 | Keybanc | Maintained | Overweight | Overweight |
| Jul 22, 2026 | Morgan Stanley | Maintained | Equal-Weight | Equal-Weight |
| Jun 18, 2026 | TD Cowen | Maintained | Buy | Buy |
| May 7, 2026 | Citigroup | Maintained | Buy | Buy |
| May 7, 2026 | JP Morgan | Maintained | Overweight | Overweight |
| Apr 15, 2026 | Citigroup | Initiated | — | Buy |
| Feb 25, 2026 | Morgan Stanley | Maintained | Equal-Weight | Equal-Weight |
| Feb 25, 2026 | Keybanc | Maintained | Overweight | Overweight |
| Feb 24, 2026 | Leerink Partners | Maintained | Outperform | Outperform |
| Feb 19, 2026 | JP Morgan | Maintained | Overweight | Overweight |
| Jan 22, 2026 | Piper Sandler | Upgrade | Neutral | Overweight |
| Dec 18, 2025 | Morgan Stanley | Maintained | Equal-Weight | Equal-Weight |
| Dec 9, 2025 | Barclays | Initiated | — | Overweight |
| Nov 21, 2025 | Keybanc | Initiated | — | Overweight |
| Nov 6, 2025 | UBS | Maintained | Buy | Buy |
| Oct 20, 2025 | UBS | Maintained | Buy | Buy |
| Oct 7, 2025 | JP Morgan | Upgrade | Neutral | Overweight |
| Sep 24, 2025 | Stifel | Maintained | Buy | Buy |
| Aug 11, 2025 | Piper Sandler | Maintained | Neutral | Neutral |
| Aug 8, 2025 | UBS | Maintained | Buy | Buy |
| Jul 23, 2025 | UBS | Maintained | Buy | Buy |
| Jul 17, 2025 | Leerink Partners | Upgrade | Market Perform | Outperform |
| Jul 2, 2025 | Stifel | Maintained | Buy | Buy |
| Jun 26, 2025 | William Blair | Upgrade | Market Perform | Outperform |
| May 19, 2025 | Stifel | Maintained | Buy | Buy |
| May 8, 2025 | Stifel | Maintained | Buy | Buy |